Lower-Dose drug may make stem cell transplants safer for blood cancer patients
NCT ID NCT06926595
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 41 adults and give them the lower dose along with two other drugs. The goal is to see if this approach works as well as higher doses but with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide (low-dose), tacrolimus, mycophenolate mofetil
What this could lead to
If successful, this could make stem cell transplants safer and more tolerable for patients with blood cancers by reducing severe side effects from GVHD prevention.
What could go wrong
This is a small, early-phase study (41 people) with no comparison group. Lower doses might not prevent GVHD as well, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••